Read your latest personalised notifications
No account yet? Start here
Don't miss out
Ok, got it
"Alirocumab is the first nonstatin that appears to reduce additional cardiovascular events on top of statin therapy, and this is very encouraging since previous trials of various lipid-lowering and other drugs have failed to find this,” said principal investigator Jennifer Robinson, MD, from the University of Iowa, Iowa City, IA, in the USA.
“Given the data available, alirocumab should prove a useful addition for lowering low density lipoprotein cholesterol (LDL-C) in high risk patients, including those with genetic high cholesterol or who cannot tolerate the recommended dose of statin.”
“We still need to see the results of the ongoing long-term cardiovascular outcomes trial to determine whether alirocumab should be routinely added to statin therapy to further reduce cardiovascular risk in high risk patients,” noted Dr. Robinson.
Our mission: To reduce the burden of cardiovascular disease
© 2018 European Society of Cardiology. All rights reserved